Therasphere for Unresectable Primary or Secondary Liver Neoplasia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02960620 |
|
Expanded Access Status :
Available
First Posted : November 9, 2016
Last Update Posted : February 3, 2021
|
Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Biocompatibles UK Ltd
BTG International Inc.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | November 8, 2016 | ||||
| First Posted Date | November 9, 2016 | ||||
| Last Update Posted Date | February 3, 2021 | ||||
| Descriptive Information | |||||
| Brief Title | Therasphere for Unresectable Primary or Secondary Liver Neoplasia | ||||
| Brief Summary | This is not a research study. The purpose is to provide supervised access to TheraSphere® therapy at this institution. | ||||
| Detailed Description | Not Provided | ||||
| Study Type | Expanded Access | ||||
| Intervention | Device: TheraSphere Treatment
TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Expanded Access Status | Available | ||||
| Contacts |
|
||||
| Listed Location Countries | United States | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT02960620 | ||||
| Responsible Party | H. Lee Moffitt Cancer Center and Research Institute | ||||
| Study Sponsor | H. Lee Moffitt Cancer Center and Research Institute | ||||
| Collaborators |
|
||||
| Investigators |
|
||||
| PRS Account | H. Lee Moffitt Cancer Center and Research Institute | ||||
| Verification Date | February 2021 | ||||